<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13322">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960907</url>
  </required_header>
  <id_info>
    <org_study_id>CHROMEDB</org_study_id>
    <nct_id>NCT01960907</nct_id>
  </id_info>
  <brief_title>Clinical Trials for Elderly Patients With Multiple Disease</brief_title>
  <acronym>CHROMED</acronym>
  <official_title>Clinical Trials for Elderly Patients With Multiple Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Restech Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lincoln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tallin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of Sezana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tesan spa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Restech Srl</source>
  <oversight_info>
    <authority>Estonia: Research Ethics Committee</authority>
    <authority>Slovenia: Ethics Committee</authority>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CHROMED project focuses its investigation on the applicability of an integrated solution
      for a pathological condition which: a) is very prevalent in ageing patients and b) severely
      impairs quality of life: COPD with other typical comorbidities such as congestive heart
      failure and sleep disordered breathing. A specific ICT platform in combination with a set of
      innovative devices will be used to collect and process useful clinical data at the patient's
      home and used to optimize their medical treatment. To evaluate the impact of this solution,
      an international multi-centric randomized control trial will be implemented in five European
      regions: United Kingdom, Sweden, Estonia, Spain and Slovenia, representing different social
      and organizational contexts in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Increase of time since first hospitalization</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>An increase of 25% in the time since first hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in patient health status</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 15% improvement in the health status of patients in the active management group quantified by the final score of the EQ-5D questionnaire</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Sleep Disordered Breathing</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
They will follow their usual care path as provided by their local NHS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a system form monitoring their health status.
The system is composed by:
a touch-screen pc for the administration of daily questionnaires
RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern
a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
Subjects will receive medical treatment following the activation of alarms by the monitoring devices.
Monthly phone interviews will be performed to collect data about their level of utilization of the health care system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CHROMED monitoring system</intervention_name>
    <description>Optimization of patient's treatment according to the data collected by the home monitoring devices</description>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD GOLD grade II or higher with a prior history of exacerbations and/or an
             hospitalization for COPD in the previous year with one or more documented
             non-pulmonary chronic conditions such as:

          -  CHF due to left ventricular systolic dysfunction (LVSD) confirmed on echocardiography

          -  SDB identified by respiratory sleeping studies or polysomnography

          -  current or prior smoking history of &gt;= 10 pack/years

          -  subjects capable of providing signed written informed consent

          -  subjects capable of perform study procedures and use the RESMONPRO at home

          -  subjects with reliable mobile phone coverage at home

        Exclusion Criteria:

          -  Any disease that, in the opinion of the investigator, put the subject at risk

          -  subjects with significant vision disturbance and mental diseases

          -  subjects with a planned prolonged absence from home
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Calverley, Phd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Clinical Medicine</name>
      <address>
        <city>Tallin</city>
        <zip>12618</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Sepper, PhD</last_name>
      <email>ruth.sepper@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kaiu Prikk, PhD</last_name>
      <email>kaiu.prikk@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ruth Sepper, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaiu Prikk, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bolnisnica Sežana Zavod</name>
      <address>
        <city>Sežana</city>
        <zip>6210</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvana Šonc</last_name>
      <email>silvana.sonc@bsezana.si</email>
    </contact>
    <investigator>
      <last_name>Silvana Šonc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorijan Marušič, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Isetta, PhD</last_name>
      <email>valentina.isetta@ub.edu</email>
    </contact>
    <investigator>
      <last_name>Valentina Isetta, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramon Farre', PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Montserrat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Malinovschi, PhD</last_name>
      <email>andrei.malinovschi@medsci.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Katarina Nisser</last_name>
      <email>Katarina.Nisser@medsci.uu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Andrei Malinovschi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chister Janson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lincolnshire Community Health Service</name>
      <address>
        <city>Lincoln</city>
        <zip>LN6 7TS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niroshan Siriwardena, MD</last_name>
      <email>nsiriwardena@lincoln.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jo Middlemass</last_name>
      <email>jmiddlemass@lincoln.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Niroshan Siriwardena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Calverley, PhD, MD</last_name>
      <email>pmacal@liverpool.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Paul Walker, MD</last_name>
      <email>PAUL.WALKER@aintree.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Calverley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.chromed.eu/</url>
    <description>Official website of the CHROMED project</description>
  </link>
  <reference>
    <citation>Brouwer AF, Visser CA, Duiverman EJ, Roorda RJ, Brand PL. Is home spirometry useful in diagnosing asthma in children with nonspecific respiratory symptoms? Pediatr Pulmonol. 2010 Apr;45(4):326-32. doi: 10.1002/ppul.21183.</citation>
    <PMID>20196110</PMID>
  </reference>
  <reference>
    <citation>Dellacà RL, Santus P, Aliverti A, Stevenson N, Centanni S, Macklem PT, Pedotti A, Calverley PM. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J. 2004 Feb;23(2):232-40.</citation>
    <PMID>14979497</PMID>
  </reference>
  <reference>
    <citation>Dellacà RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J. 2009 Jun;33(6):1329-37. Epub 2009 Jan 22.</citation>
    <PMID>19164347</PMID>
  </reference>
  <reference>
    <citation>Dellacà R, Montserrat JM, Govoni L, Pedotti A, Navajas D, Farré R. Telemetric CPAP titration at home in patients with sleep apnea-hypopnea syndrome. Sleep Med. 2011 Feb;12(2):153-7. doi: 10.1016/j.sleep.2010.07.014. Epub 2011 Jan 17. PubMed PMID: 21247800.</citation>
    <PMID>21247800</PMID>
  </reference>
  <reference>
    <citation>Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004 Jun 15;169(12):1298-303. Epub 2004 Feb 27.</citation>
    <PMID>14990395</PMID>
  </reference>
  <reference>
    <citation>McKinstry B, Pinnock H, Sheikh A. Telemedicine for management of patients with COPD? Lancet. 2009 Aug 29;374(9691):672-3. doi: 10.1016/S0140-6736(09)61542-7. Review.</citation>
    <PMID>19716948</PMID>
  </reference>
  <reference>
    <citation>Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010 Nov;65(11):956-62. doi: 10.1136/thx.2009.128082. Epub 2010 Sep 25.</citation>
    <PMID>20871122</PMID>
  </reference>
  <reference>
    <citation>Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990 Dec;38(12):1290-5.</citation>
    <PMID>2254567</PMID>
  </reference>
  <reference>
    <citation>MacDonald M, Fang J, Pittman SD, White DP, Malhotra A. The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers. J Clin Sleep Med. 2008 Feb 15;4(1):38-42.</citation>
    <PMID>18350960</PMID>
  </reference>
  <reference>
    <citation>Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K, Scott RE. Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Telemed Telecare. 2010;16(3):120-7. doi: 10.1258/jtt.2009.090812. Epub 2010 Mar 2. Review.</citation>
    <PMID>20197355</PMID>
  </reference>
  <reference>
    <citation>Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail. 2006 Nov;8(7):706-11. Epub 2006 Mar 13. Review.</citation>
    <PMID>16531114</PMID>
  </reference>
  <reference>
    <citation>Calverley P, Pauwels Dagger R, Löfdahl CG, Svensson K, Higenbottam T, Carlsson LG, Ståhl E. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J. 2005 Sep;26(3):406-13. Erratum in: Eur Respir J. 2006 Feb;27(2):440.</citation>
    <PMID>16135720</PMID>
  </reference>
  <reference>
    <citation>Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698-702.</citation>
    <PMID>15176682</PMID>
  </reference>
  <reference>
    <citation>McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009 Oct 15;180(8):692-700. doi: 10.1164/rccm.200903-0347PP. Epub 2009 Jul 23.</citation>
    <PMID>19628778</PMID>
  </reference>
  <reference>
    <citation>Johnson MK, Birch M, Carter R, Kinsella J, Stevenson RD. Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry. Thorax. 2007 Apr;62(4):299-306. Epub 2006 Nov 14.</citation>
    <PMID>17105778</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 12, 2013</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Restech Srl</investigator_affiliation>
    <investigator_full_name>Pasquale Pio Pompilio</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>CHF</keyword>
  <keyword>SDB</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
